Holen Sie sich die Stockscreener-App
1.07
0.93%
-0.01
Handel nachbörslich:
1.08
0.01
+0.93%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt LXRX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$1.08
Offen:
$1.08
24-Stunden-Volumen:
1.52M
Relative Volume:
0.43
Marktkapitalisierung:
$388.84M
Einnahmen:
$1.21M
Nettoeinkommen (Verlust:
$-177.12M
KGV:
-1.3375
EPS:
-0.8
Netto-Cashflow:
$-162.37M
1W Leistung:
-6.96%
1M Leistung:
-4.46%
6M Leistung:
+229.43%
1J Leistung:
-34.36%
1-Tages-Spanne:
$1.03
$1.09
1-Wochen-Bereich:
$1.03
$1.20
52-Wochen-Spanne:
$0.2836
$2.175
Lexicon Pharmaceuticals Inc Stock (LXRX) Company Profile
Firmenname
Lexicon Pharmaceuticals Inc
Sektor
Branche
Telefon
(281) 863-3000
Adresse
2445 TECHNOLOGY FOREST BLVD., THE WOODLANDS
Vergleichen Sie LXRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LXRX
Lexicon Pharmaceuticals Inc
|
1.07 | 407.01M | 1.21M | -177.12M | -162.37M | -0.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Lexicon Pharmaceuticals Inc Stock (LXRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-05 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-06-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-04-30 | Eingeleitet | Leerink Partners | Outperform |
| 2023-03-07 | Eingeleitet | Jefferies | Hold |
| 2022-08-12 | Eingeleitet | Piper Sandler | Overweight |
| 2021-01-29 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-01-29 | Herabstufung | Wedbush | Outperform → Neutral |
| 2020-12-08 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-11-18 | Hochstufung | Gabelli & Co | Hold → Buy |
| 2019-12-11 | Herabstufung | Gabelli & Co | Buy → Hold |
| 2019-11-08 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-09-11 | Hochstufung | Gabelli & Co | Hold → Buy |
| 2019-07-29 | Herabstufung | Stifel | Buy → Hold |
| 2019-03-25 | Hochstufung | Gabelli & Co | Sell → Hold |
| 2018-07-31 | Bestätigt | Stifel | Buy |
| 2018-02-23 | Herabstufung | Needham | Buy → Hold |
| 2018-02-14 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2017-03-01 | Bestätigt | H.C. Wainwright | Buy |
| 2017-03-01 | Bestätigt | Wedbush | Outperform |
| 2016-10-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-08-05 | Bestätigt | Wedbush | Outperform |
| 2016-08-02 | Eingeleitet | Citigroup | Buy |
| 2016-03-02 | Bestätigt | Wedbush | Outperform |
| 2015-11-09 | Bestätigt | Wedbush | Outperform |
| 2015-09-28 | Hochstufung | Gabelli & Co | Sell → Hold |
| 2015-09-18 | Herabstufung | Gabelli & Co | Hold → Sell |
| 2015-08-10 | Herabstufung | JP Morgan | Overweight → Neutral |
Alle ansehen
Lexicon Pharmaceuticals Inc Aktie (LXRX) Neueste Nachrichten
Lexicon Pharmaceuticals' Strategic R&D Pivots and Licensing Catalysts in 2025 - AInvest
Lexicon Pharmaceuticals' Strategic Positioning in the Biopharma Sector - AInvest
Can Lexicon Pharmaceuticals Inc. generate free cash flow2025 Valuation Update & Weekly High Conviction Ideas - khodrobank.com
Lexicon Pharmaceuticals Announces Presentation of Diabetic Peripheral Neuropathic Pain Patient Insights at PAINWeek 2025 - The Manila Times
Lexicon Pharmaceuticals to Present Patient Insights on Diabetic Peripheral Neuropathic Pain at PAINWeek 2025 - Quiver Quantitative
30% of Diabetics Suffer Neuropathic Pain: Lexicon Study Reveals Impact on Daily Life at PAINWeek - Stock Titan
H.C. Wainwright reiterates Buy rating on Lexicon Pharmaceuticals stock at $4 - Investing.com
How to use a screener to detect Lexicon Pharmaceuticals Inc. breakouts2025 Performance Recap & High Accuracy Trade Alerts - Newser
Using Python tools to backtest Lexicon Pharmaceuticals Inc. strategiesEarnings Beat & Risk Controlled Swing Trade Alerts - Newser
Pattern recognition hints at Lexicon Pharmaceuticals Inc. upsideMarket Sentiment Report & Real-Time Chart Pattern Alerts - Newser
Can trapped investors hope for a rebound in Lexicon Pharmaceuticals Inc.July 2025 Institutional & Momentum Based Trading Ideas - Newser
Update Recap: Can Lexicon Pharmaceuticals Inc. reach all time highs this year2025 Valuation Update & Real-Time Market Trend Scan - khodrobank.com
How to build a dashboard for Lexicon Pharmaceuticals Inc. stockMarket Trend Report & AI Optimized Trading Strategy Guides - Newser
Buybacks Report: What’s the MACD signal for Lexicon Pharmaceuticals Inc.Market Volume Summary & Technical Entry and Exit Alerts - khodrobank.com
Price action breakdown for Lexicon Pharmaceuticals Inc.Market Movement Recap & High Accuracy Swing Entry Alerts - Newser
Is Lexicon Pharmaceuticals Inc. meeting your algorithmic filter criteriaLong Setup & Safe Capital Growth Stock Tips - Newser
28% Heart Failure Risk Reduction: Lexicon's Sotagliflozin Proves Equally Effective in Elderly Patients Over 75 - Stock Titan
Ideas Watch: Is Lexicon Pharmaceuticals Inc. benefiting from innovation trendsJuly 2025 Market Mood & Community Trade Idea Sharing Platform - khodrobank.com
Combining price and volume data for Lexicon Pharmaceuticals Inc.2025 Trade Ideas & Weekly Momentum Picks - Newser
What is Lexicon Pharmaceuticals Inc.’s valuation compared to sectorPortfolio Return Summary & Safe Capital Growth Trade Ideas - khodrobank.com
Can Lexicon Pharmaceuticals Inc. ride the EV waveRate Cut & Daily Entry Point Alerts - khodrobank.com
What is Lexicon Pharmaceuticals Inc.’s TAM (Total Addressable Market)July 2025 Intraday Action & Real-Time Volume Trigger Notifications - khodrobank.com
Analysts Backtest Strategies on Lexicon Pharmaceuticals Inc. With Promising Results getLinesFromResByArray error: size == 0 - kangso.co.kr
What’s the RSI of Lexicon Pharmaceuticals Inc. stockQuarterly Profit Report & Real-Time Buy Zone Alerts - khodrobank.com
MACD Cross Could Confirm Trend in Lexicon Pharmaceuticals Inc.2025 Geopolitical Influence & Target Return Focused Stock Picks - beatles.ru
Visual analytics tools that track Lexicon Pharmaceuticals Inc. performanceMarket Growth Report & Fast Momentum Stock Entry Tips - Newser
Measuring Lexicon Pharmaceuticals Inc.’s beta against major indices2025 Buyback Activity & Reliable Momentum Entry Alerts - Newser
Should you hold or exit Lexicon Pharmaceuticals Inc. nowJuly 2025 Macro Moves & Safe Capital Growth Stock Tips - Newser
Heatmap analysis for Lexicon Pharmaceuticals Inc. and competitors2025 Market WrapUp & Weekly High Return Stock Forecasts - Newser
Can momentum traders help lift Lexicon Pharmaceuticals Inc.July 2025 Recap & Expert Curated Trade Ideas - Newser
Strategies to average down on Lexicon Pharmaceuticals Inc.July 2025 Retail & Weekly High Return Opportunities - Newser
Will Lexicon Pharmaceuticals Inc. outperform tech stocksJuly 2025 Summary & Stepwise Trade Signal Guides - sundaytimes.kr
Analyzing net buyer seller activity in Lexicon Pharmaceuticals Inc.Quarterly Trade Report & Fast Moving Stock Watchlists - Newser
Real time alert setup for Lexicon Pharmaceuticals Inc. performanceIndex Update & Reliable Price Breakout Alerts - Newser
Will Lexicon Pharmaceuticals Inc. face regulatory challenges2025 Short Interest & Step-by-Step Swing Trade Plans - kpenews.com
Top chart patterns to watch in Lexicon Pharmaceuticals Inc.July 2025 EndofMonth & Weekly Momentum Stock Picks - Newser
Exit strategy if you’re trapped in Lexicon Pharmaceuticals Inc.Trade Risk Report & Growth Oriented Trade Recommendations - Newser
How to escape a deep drawdown in Lexicon Pharmaceuticals Inc.Weekly Gains Summary & Risk Adjusted Buy/Sell Alerts - Newser
Finanzdaten der Lexicon Pharmaceuticals Inc-Aktie (LXRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Lexicon Pharmaceuticals Inc-Aktie (LXRX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Sullivan Diane E. | Director |
May 13 '25 |
Option Exercise |
0.00 |
36,810 |
0 |
36,810 |
| SOBECKI CHRISTOPHER J | Director |
May 13 '25 |
Option Exercise |
0.00 |
36,810 |
0 |
203,865 |
| BARKER SAM L | Director |
May 13 '25 |
Option Exercise |
0.00 |
36,810 |
0 |
124,459 |
| Amouyal Philippe | Director |
May 13 '25 |
Option Exercise |
0.00 |
36,810 |
0 |
285,174 |
| DEBBANE RAYMOND | Director |
May 13 '25 |
Option Exercise |
0.00 |
36,810 |
0 |
1,385,689 |
1.75%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):